Metropolitan Life Insurance Co. NY Buys 8,682 Shares of Intellia Therapeutics Inc (NTLA)

Metropolitan Life Insurance Co. NY raised its holdings in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) by 356.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,116 shares of the company’s stock after buying an additional 8,682 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in Intellia Therapeutics were worth $152,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of NTLA. We Are One Seven LLC acquired a new position in Intellia Therapeutics in the fourth quarter valued at about $28,000. Patriot Financial Group Insurance Agency LLC lifted its stake in Intellia Therapeutics by 35.8% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 5,495 shares of the company’s stock valued at $75,000 after buying an additional 1,450 shares during the period. Nikko Asset Management Americas Inc. lifted its stake in Intellia Therapeutics by 20.0% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 5,980 shares of the company’s stock valued at $82,000 after buying an additional 995 shares during the period. Pacer Advisors Inc. acquired a new position in Intellia Therapeutics in the third quarter valued at about $216,000. Finally, SG Americas Securities LLC acquired a new position in Intellia Therapeutics in the fourth quarter valued at about $112,000. Institutional investors own 71.65% of the company’s stock.

In other news, EVP Andrew Schiermeier purchased 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was acquired at an average cost of $15.72 per share, with a total value of $117,900.00. Following the acquisition, the executive vice president now owns 3,250 shares in the company, valued at approximately $51,090. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 4.10% of the company’s stock.

NTLA stock traded down $0.04 during mid-day trading on Friday, reaching $16.12. The company had a trading volume of 450,714 shares, compared to its average volume of 597,258. Intellia Therapeutics Inc has a 52 week low of $11.03 and a 52 week high of $32.95. The company has a market cap of $738.69 million, a price-to-earnings ratio of -8.14 and a beta of 2.79. The company has a quick ratio of 8.01, a current ratio of 7.74 and a debt-to-equity ratio of 0.06.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.53) by $0.04. Intellia Therapeutics had a negative return on equity of 31.68% and a negative net margin of 257.28%. The company had revenue of $10.43 million during the quarter, compared to analysts’ expectations of $9.43 million. During the same period last year, the firm posted ($0.51) earnings per share. The business’s revenue was up 39.7% on a year-over-year basis. On average, equities research analysts anticipate that Intellia Therapeutics Inc will post -2.49 EPS for the current fiscal year.

Several equities research analysts have issued reports on the company. Chardan Capital restated a “buy” rating and issued a $57.50 price target on shares of Intellia Therapeutics in a report on Wednesday, February 27th. BTIG Research started coverage on Intellia Therapeutics in a report on Thursday, February 7th. They issued a “buy” rating and a $20.00 price target for the company. BidaskClub upgraded Intellia Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, April 5th. Zacks Investment Research downgraded Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 29th. Finally, Wedbush upgraded Intellia Therapeutics from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $20.00 to $21.00 in a report on Friday, May 3rd. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating to the stock. Intellia Therapeutics currently has an average rating of “Hold” and an average price target of $29.25.

TRADEMARK VIOLATION NOTICE: “Metropolitan Life Insurance Co. NY Buys 8,682 Shares of Intellia Therapeutics Inc (NTLA)” was published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.baseballdailydigest.com/news/2019/05/11/metropolitan-life-insurance-co-ny-has-152000-stake-in-intellia-therapeutics-inc-ntla.html.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.

See Also: What is a trade deficit?

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.